Pharmacokinetic/Pharmacodynamic Modeling in Drug Development, Annual Review of Pharmacology and Toxicology, vol.40, issue.1, pp.67-95, 2000. ,
DOI : 10.1146/annurev.pharmtox.40.1.67
Role of modelling and simulation in Phase I drug development, European Journal of Pharmaceutical Sciences, vol.13, issue.2, pp.115-122, 2001. ,
DOI : 10.1016/S0928-0987(01)00096-3
Application of pharmacokinetic/pharmacodynamic modelling and population approaches to drug development, International J. of Pharmaceutical Medicine, vol.13, pp.243-251, 1999. ,
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans, Pharmaceutical Research, vol.17, issue.11, pp.1335-1344, 2000. ,
DOI : 10.1023/A:1007574217260
Simulation for designing clinical trials: a pharmacokineticpharmacodynamic modeling prospective, 2003. ,
Guidance for Industry: population pharmacokinetics, 1999. ,
Stability and Performance of a Population Pharmacokinetic Model, The Journal of Clinical Pharmacology, vol.87, issue.6, pp.486-495, 1997. ,
DOI : 10.1002/j.1552-4604.1997.tb04326.x
Determination of model appropriateness Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check, J. Pharmacokinet. Pharmacodyn, vol.2801, issue.10, pp.171-0406, 2003. ,
Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.4, pp.257-283, 2003. ,
DOI : 10.1023/A:1026142601822
URL : https://hal.archives-ouvertes.fr/inserm-00189555
Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001. ,
DOI : 10.1023/A:1012299115260
Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers, Biopharmaceutics & Drug Disposition, vol.6, issue.4, pp.151-157, 2002. ,
DOI : 10.1002/bdd.303
An improved Bonferroni procedure for multiple tests of significance, Biometrika, vol.73, issue.3, pp.751-764, 1986. ,
DOI : 10.1093/biomet/73.3.751
NONMEM Users Guides (I-VIII), Globomax LLC, 1989. ,
Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method, Journal of Pharmacokinetics and Biopharmaceutics, vol.26, issue.2, pp.133-161, 1998. ,
DOI : 10.1023/A:1020505722924
EVALUATION OF TESTS BASED ON INDIVIDUAL VERSUS POPULATION MODELING TO COMPARE DISSOLUTION CURVES, Journal of Biopharmaceutical Statistics, vol.11, issue.3, pp.107-123, 2001. ,
DOI : 10.1081/BIP-100107652
Validation of population pharmacokinetic/pharmacodynamic analyses: review of proposed approaches. The population approach: measuring and 04, p.6 ,
Bayesian data analysis, 1995. ,
Conditional weighted residuals. A diagnostic to improve population PK/PD model building and evaluation, AAPS J, vol.7, issue.S2, p.5321, 2005. ,
P values for composite null models Assymptotic distribution of P values in composite null models, JASA. JASA, vol.95, issue.95, pp.1143-11721143, 2000. ,
Assymptotic distribution of P values in composite null models A linear mixed-effects models with heterogeneity in random effects population, JASA. JASA, vol.95, issue.91, pp.1143-1172217, 1996. ,
A Linear Mixed-Effects Model with Heterogeneity in the Random-Effects Population, Journal of the American Statistical Association, vol.86, issue.433, pp.217-221, 1996. ,
DOI : 10.1080/01621459.1989.10478736